By Bachem AG
To get in touch with Bachem brings its latest peptide generic APIs and selective glycosylation technology to CPhI Worldwide, simply fill out the form below.
Subscribe to Supplier
Bachem brings its latest peptide generic APIs and selective glycosylation technology to CPhI Worldwide
Bubendorf, Switzerland: – Peptide technology specialist Bachem AG will be showing its wide range of active pharmaceutical ingredients (APIs) and innovative selective glycosylation technology at Europe’s leading pharma fair, CPhI Worldwide.
Bachem’s stand at Booth #7H14 in Hall 7 at the Fira de Barcelona Center will present opportunities to harness its innovative peptide generic APIs and proprietary processes.
Bachem is a trusted supplier of peptide and small molecule generics. With over 80 DMF filings and more in the pipeline they support the success of their partners. Its pipeline contains more than 200 customer projects in preclinical and clinical phases. They all have promising potential: in the last two years, a number of products in phase III trials received marketing authorization and phase II projects progressed to pivotal phase III clinical trials.
These include its recently introduced selective chemical glycosylation service, using technology co-developed with GlyTech, Inc., of Japan. The service is applicable to large-scale production with potential application to a variety of peptide-based future drugs.
The process was explained in a recent X-Talks webinar, presented by GlyTech board adviser, Dr. Michael F. Haller, Ph.D., who provided insights on how the selective glycosylation can improve physicochemical properties of peptides.
Pioneering peptide partner
“We are delighted to be returning to CPhI Worldwide,” said Dr. Martina Diekmann, VP Global Marketing, who will be a leading member of the company’s team at the conference.
“Our team will be busy throughout CPhI, using the great networking opportunities to discuss potential collaborations that can harness our outstanding knowledge of peptide and organic chemistry and explaining how our mission ‘Pioneering Partner for Peptides’ can actively support clients through all phases of drug development,” said Dr. Diekmann.
“We have a very strong offer to present, including FDA certified cGMP manufacturing facilities with capacity to produce peptide generic APIs from gram scale up to annual quantities of hundreds of kilograms, along with a very impressive regulatory background that allows us to provide full support with required regulatory documentation,” said Dr. Diekmann.
Bachem will present: “The Bachem Approach to Quality By Design (QBD)” at the Exhibitor Showcase, on October 4, 2016 and is also sponsoring the Innovation Award in the “Global Generics and Biosimilars Awards 2016” category.
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients (APIs). A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Germany, the UK, and the USA, the group specializes in process development and the manufacture of peptides and complex organic molecules as APIs as well as innovative biochemicals for research.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, new chemical entities (NCEs) and finished dosage forms at preclinical, clinical and production scales.
About CPhI Worldwide 2016
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitor opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends.
Now in its 27th year, the 2016 fair is a three-day event opening October 4 at the Fira de Barcelona exhibition center. Last year’s event in Madrid attracted some 36,000 delegates and 2,500 exhibitor companies from more than 150 countries worldwide.
The CPhl Worldwide show is being held alongside three other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events.
The Pre-Connect Conference on October 3 brings together senior stakeholders from all segments of the industry for a series of market-led educational modules on latest trends and topics while the CPhI Pharma Awards, presented on the first evening of the conference, honor innovative companies and leaders.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live
More information at: http://www.cphi.com/europe/
Dr. Martina Diekmann, Head of Global Marketing, Bachem Group
Tel: +41 799 459 107
Click on Bachem brings its latest peptide generic APIs and selective glycosylation technology to CPhI Worldwide for more information.
Click on Bachem to contact the company directly.
Click on Bachem Video to see latest corporate presentation.
Click on Chemical Synthesis to see Webinar abstract.